What Is The Current and Historic Market Size Analysis Of The Osimertinib Drugs Market?
The osimertinib drugs market has seen considerable growth due to a variety of factors.
• The market size for osimertinib drugs has swiftly expanded in the past few years. Expectations are that it will rise from $6.66 billion in 2024 to $7.82 billion in 2025, representing a compound annual growth rate (CAGR) of 17.4%.
The historical growth is credited to factors like investments in research and development, the launch of targeted therapies, successful clinical trials, resistance to earlier treatments, and an enhanced safety profile.
What Is The Forecast For The Osimertinib Drugs Market Size?
The osimertinib drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of osimertinib drugs is anticipated to expand swiftly in the upcoming years, increasing to $14.05 billion by 2029 at a compound annual growth rate (CAGR) of 15.8%.
The growth during this forecast period can be ascribed to improvements in patient-centric care, ongoing clinical trials and research, the inclusion of precision medicine, initiatives for pricing and access, and global market expansion. The forecast period will also see significant trends such as the entry of biosimilars and market competition, the adoption of liquid biopsy, advances in genomic profiling, strategies for resistance management, and trials of immunotherapy combinations.
What Are The Essential Drivers Behind The Growth Of The Osimertinib Drugs Market?
The rise in lung cancer cases is anticipated to drive the osimertinib drug market's expansion. Lung cancer, which predominantly originates in the lung tissue's cells lining the airways, is increasingly being treated with osimertinib. This drug works by inhibiting the activity of specific proteins involved in cancer cell growth and dispersion. In 2022, the American Cancer Society reported about 236,740 lung cancer diagnoses in the US, a figure that grew to 238,340 by 2023. This escalating incidence of lung cancer enhances the growth prospects for the osimertinib drug market. Efforts by organizations to improve lung cancer care and treatment are also expected to fuel the osimertinib drug market's growth. These efforts, which come in the form of policies, funding, and programs, aim to boost the accessibility, affordability, and quality of care for cancer patients, with a particular focus on better usage of the drug osimertinib. An example of such an initiative is the National Lung Cancer Screening Program (NLCSP), implemented by The Australian Department of Health and Aged Care in May 2024. This program uses low-dose computed tomography (LDCT) scans for early lung cancer detection, targeting primarily individuals aged 50 to 80 with a significant smoking history. Consequently, these proactive initiatives to enhance lung cancer care and treatment contribute significantly to the osimertinib drug market's expansion.
How Is The Global Osimertinib Drugs Market Divided Into Key Segments?
The osimertinib drugs market covered in this report is segmented –
1) By Type: 40 mg, 80 mg
2) By Distribution Channel: Hospital Pharmacy, Drug Store And Retail Pharmacy, Online Pharmacy
3) By Application: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Other Applications
Pre-Book The Osimertinib Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Osimertinib Drugs Market?
Leading firms in the osimertinib drugs market are concentrating on targeted therapies to enhance results for non-small cell lung cancer (NSCLC) patients, particularly those with EGFR mutations. Their objective is to boost treatment efficacy and the quality of life for patients. They are also channeling resources into clinical trials and research collaborations to broaden the scope of osimertinib's applications and investigate its combined effectiveness with other therapies for the greater good of patients. For instance, in September 2024, AstraZeneca Pharmaceuticals LP, a pharmaceutical organization based in the US, introduced osimertinib (Tagrisso) for adult patients with locally advanced, non-resectable non-small cell lung cancer (NSCLC) with FDA-approved specific EGFR mutations. This authorization was preceded by a clinical study that showed notable advances in progression-free survival compared to a placebo.
Who Are the Key Players In The Osimertinib Drugs Market?
Major companies operating in the osimertinib drugs market report are:
• Syndax Pharmaceuticals Ltd.
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• AstraZeneca PLC
• Amgen Inc.
• Sandoz International GmbHIncyte Corporation
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Seagen Inc.
• Zydus Lifesciences Limited
• Sun Pharmaceutical Industries Ltd.
• Alembic Pharmaceuticals Limited
• Aristo Pharmaceuticals Private LimitedIncepta Pharmaceuticals Ltd.
• Accord Healthcare Limited
• Asmo Corporation
• Beacon Pharmaceutical Limited
• Clearsynth Labs Limited
• Apino Pharma Co. Ltd.
• Kay Biotech Private Limited
• Drug International Limited
• MSN Laboratories Pvt Ltd.
• Array BioPharma Inc.
• Dolphin Pharmaceutical Limited
• Hetero Drugs Ltd.
• Serum Biotech Limited
• Zenix Remedies
• Accure Labs Pvt. Ltd.
What Are The Regional Insights Into The Osimertinib Drugs Market?
North America was the largest region in the osimertinib drugs market in 2024. The regions covered in the osimertinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
